Once monthly dose of Actonel has been approved to treating and preventing postmenopausal osteoporosis.
The Agency okayed the new dosage on the basis of a study of 642 women that compared 150 mg of Actonel monthly to 5 mg daily of the tablet. The study showed similar increases for both groups in lumbar spine bone mineral density and at other sites from baseline at 1 year. Produced by Procter and Gamble Pharmaceuticals, the drug is marketed by Sanofi-Aventis U.S. For more information on Actonel, visit the Web site at http://www.actonel.com/.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More